Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Inspire Pharmaceuticals' denufosol showed improvement in FEV1 versus placebo over 24 weeks.
Advertisement

Related Content

Stockwatch: The TIGER That Came To Lilly
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
PTC Advances Cystic Fibrosis Candidate On Encouraging Data
PTC Advances Cystic Fibrosis Candidate On Encouraging Data
Inspire Drops Epinastine After Phase III Fizzle
Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease
Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease
Inspire Terminates Deal With FAES Farma For Oral Bilastine

Topics

Advertisement
UsernamePublicRestriction

Register

PS068040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel